Budget Impact Analysis of Using Dihydroartemisinin–Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania

PharmacoEconomics

Volumn 34, Issue 3, 2016, Pages 303-314

  Mori, Amani Thomas ^a,b   Norheim, Ole Frithjof ^a   Robberstad, Bjarne ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ARTICLE; BUDGET; BUDGET IMPACT ANALYSIS; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HELP SEEKING BEHAVIOR; HUMAN; MALARIA; PRIORITY JOURNAL; TANZANIA; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; INFANT; MARKOV CHAIN; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FLUORENES; HEALTH CARE COSTS; HUMANS; INFANT; MALARIA; MARKOV CHAINS; MODELS, ECONOMIC; QUINOLINES; TANZANIA;

EID: 84959146782     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-015-0344-1     Document Type: Article

References (58)

1. WHO. World malaria report 2014. Geneva: World Health Organization; 2014.
2. D’Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Maro J, et al. Beyond malaria—causes of fever in outpatient Tanzanian children. N Engl J Med. 2014;370(9):809–17. doi:10.1056/NEJMoa1214482.
3. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379(9814):413–31. doi:10.1016/s0140-6736(12)60034-8.
4. Ministry of Health and Social Welfare. National guidelines for malaria diagnosis and treatment. Dar es Salaam: National Malaria Control Program; 2006.
5. Ministry of Health and Social Welfare. Standard treatment guidelines and national essential medicine list—Tanzania Mainland. 4th ed. Dar es Salaam: Ministry of Health and Social Welfare; 2013.
6. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
7. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;1:CD010927. doi:10.1002/14651858.cd010927.
8. Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606. doi:10.1038/ncomms6606.
9. Akpaloo W, Purssell E. Does the use of dihydroartemisinin-piperaquine in treating patients with uncomplicated falciparum malaria reduce the risk for recurrent new falciparum infection more than artemether-lumefantrine? Malar Res Treat. 2014;2014:263674. doi:10.1155/2014/263674.
10. Ewing VL, Terlouw DJ, Kapinda A, Pace C, Richards E, Tolhurst R, et al. Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study. Malar J. 2015;14(1):13. doi:10.1186/s12936-014-0528-8.
11. Pfeil J, Borrmann S, Tozan Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS One. 2014;9(4):e95681.
12. Mori AT, Ngalesoni F, Norheim OF, Robberstad B. Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malar J. 2014;13:363. doi:10.1186/1475-2875-13-363.
13. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291.
14. United Republic of Tanzania. The 2012 Population and Housing Census: population distribution by age and sex. Dar es-Salaam: National Bureau of Statistics and Office of Chief Government Statistician; 2013.
15. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), Nattional Bureau of Statistics (NBS), The Chief Government Statistician (OCGS), ICF International. HIV/AIDS and Malaria Indicator Survey 2011–2012. Dar es Salaam: TACAIDS, ZAC, NBS, OCGS and ICF International; 2013.
16. National Bureau of Statistics. Tanzania in figures 2012. Dar es Salaam: Ministry of Finance; 2013.
17. National Bureau of Statistics, ICF Macro. Tanzania Demographic and Health Survey 2010. Dar es Salaam: National Bureau of Statistics; 2011.
18. WHO. World health statistics. Geneva: World Health Organization; 2012.
19. Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8(11):e1001119. doi:10.1371/journal.pmed.1001119.
20. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One. 2014;9(1):e84555.
21. Yeka A, Tibenderana J, Achan J, D’Alessandro U, Talisuna AO. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PLoS One. 2013;8(1):e53772.
22. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR, Dorsey G, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ. 2009;339:b2763. doi:10.1136/bmj.b2763.
23. Abdulla S, Goodman C, Coleman P, Mubyazi G, Kikumbih N, Okorosobo T. The costs, effects and cost-effectiveness of changing the first line drug for the treatment of malaria in Tanzania. HEFP working paper 01/00. HEFP; 2000. http://r4d.dfid.gov.uk/PDF/Outputs/HealthEcFin_KP/WP01_00.pdf. Accessed 23 Oct 2015.
24. Coleman PG, Morel C, Shillcutt S, Goodman C, Mills AJ. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):196–204.
25. Committee on the Economics of Antimalarial Drugs, Board on Global Health. The cost and cost-effectiveness of antimalarial drugs. In: Arrow KJ, Panosian CB, Gelband H, editors. Saving lives, buying time: economics of malaria drugs in an age of resistance. Washington, DC: National Academies Press; 2004. pp. 61–78.
26. Kahabuka C, Kvale G, Moland KM, Hinderaker SG. Why caretakers bypass Primary Health Care facilities for child care - a case from rural Tanzania. BMC Health Serv Res. 2011;11:315. doi:10.1186/1472-6963-11-315.
27. Mikkelsen-Lopez I, Tediosi F, Abdallah G, Njozi M, Amuri B, Khatib R, et al. Beyond antimalarial stock-outs: implications of health provider compliance on out-of-pocket expenditure during care-seeking for fever in South East Tanzania. BMC Health Serv Res. 2013;13:444. doi:10.1186/1472-6963-13-444.
28. Kahabuka C, Kvale G, Hinderaker SG. Care-seeking and management of common childhood illnesses in Tanzania—results from the 2010 Demographic and Health Survey. PLoS One. 2013;8(3):e58789. doi:10.1371/journal.pone.0058789.
29. Rao VB, Schellenberg D, Ghani AC. The potential impact of improving appropriate treatment for fever on malaria and non-malarial febrile illness management in under-5s: a decision-tree modelling approach. PLoS One. 2013;8(7):e69654. doi:10.1371/journal.pone.0069654.
30. PMI. Malaria operational plan FY 2014. Dar es Salaam: President’s Malaria Initiative; 2014.
31. D’Acremont V, Kahama-Maro J, Swai N, Mtasiwa D, Genton B, Lengeler C. Reduction of anti-malarial consumption after rapid diagnostic tests implementation in Dar es Salaam: a before-after and cluster randomized controlled study. Malar J. 2011;10:107. doi:10.1186/1475-2875-10-107.
32. Mubi M, Kakoko D, Ngasala B, Premji Z, Peterson S, Bjorkman A, et al. Malaria diagnosis and treatment practices following introduction of rapid diagnostic tests in Kibaha District, Coast Region, Tanzania. Malar J. 2013;12:293. doi:10.1186/1475-2875-12-293.
33. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, et al. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ. 2007;334(7590):403. doi:10.1136/bmj.39073.496829.AE.
34. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty C, et al. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull World Health Organ. 2008;86(2):101–10. doi:10.2471/blt.07.042259.
35. Mikkelsen-Lopez I, Shango W, Barrington J, Ziegler R, Smith T, deSavigny D. The challenge to avoid anti-malarial medicine stock-outs in an era of funding partners: the case of Tanzania. Malar J. 2014;13:181. doi:10.1186/1475-2875-13-181.
36. Briggs MA, Kalolella A, Bruxvoort K, Wiegand R, Lopez G, Festo C, et al. Prevalence of malaria parasitemia and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania with ACT subsidies. PLoS One. 2014;9(4):e94074. doi:10.1371/journal.pone.0094074.
37. Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, et al. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malar J. 2005;4:55. doi:10.1186/1475-2875-4-55.
38. Adeyi O, Atun R. Universal access to malaria medicines: innovation in financing and delivery. Lancet. 2010;376(9755):1869–71. doi:10.1016/s0140-6736(10)61189-0.
39. Mbonye AK, Lal S, Cundill B, Hansen KS, Clarke S, Magnussen P. Treatment of fevers prior to introducing rapid diagnostic tests for malaria in registered drug shops in Uganda. Malar J. 2013;12:131. doi:10.1186/1475-2875-12-131.
40. Morris A, Ward A, Moonen B, Sabot O, Cohen JM. Price subsidies increase the use of private sector ACTs: evidence from a systematic review. Health Policy Plan. 2015;30(3):397–405. doi:10.1093/heapol/czu013.
41. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354(9176):378–85.
42. de Savigny D, Mayombana C, Mwageni E, Masanja H, Minhaj A, Mkilindi Y, et al. Care-seeking patterns for fatal malaria in Tanzania. Malar J. 2004;3:27. doi:10.1186/1475-2875-3-27.
43. Lubell Y, Staedke SG, Greenwood BM, Kamya MR, Molyneux M, Newton PN, et al. Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One. 2011;6(2):e17439. doi:10.1371/journal.pone.0017439.
44. Dondorp AM, Fanello CI, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–57. doi:10.1016/s0140-6736(10)61924-1.
45. The Global Fund. ACT Prices under the Affordable Medicines Facility-malaria: update of 22 May 2013. Fact sheet. Geneva: The Global Fund; 2013.
46. Management Science for Health. International drug price indicator guide. 2013th ed. Arlington: Management Science for Health, Inc.; 2014.
47. Medical Stores Department. Price catalogue of essential medicines, diagnostics and hospital supplies-2014/2015. Dar es Salaam: Medical Stores Department; 2014.
48. Bank of Tanzania. Monthly economic review: October 2014. Dar es Salaam: Bank of Tanzania; 2014.
49. Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumba M, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89(7):504–12. doi:10.2471/BLT.11.085878.
50. WHO. World malaria report 2013. Geneva: World Health Organization; 2013.
51. Lozano R, Wang H, Foreman KJ, Rajaratnam JK, Naghavi M, Marcus JR, et al. Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet. 2011;378(9797):1139–65. doi:10.1016/s0140-6736(11)61337-8.
52. Department of Policy and Planning, Ministry of Health and Social Welfare, United Republic of Tanzania. Tanzania national health accounts year 2010: with sub-accounts for HIV and AIDS, malaria, reproductive, and child health. Dar es Salaam: Department of Policy and Planning, Ministry of Health and Social Welfare, United Republic of Tanzania; 2012.
53. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost-effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009;27(11):903–17.
54. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. CHE research paper 109.York: Centre for Health Economics, University of York; 2015.
55. Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health. 2006;11(4):452–61. doi:10.1111/j.1365-3156.2006.01590.x.
56. Jowett M, Miller N, Mnzava N. Malaria expenditure analysis: Tanzania Case Study. Dar es Salaam: DFID-EA (Tanzania) and the Roll Back Malaria Initiative; 2000.
57. Kahabuka C, Kvale G, Hinderaker SG. Factors associated with severe disease from malaria, pneumonia and diarrhea among children in rural Tanzania - a hospital-based cross-sectional study. BMC Infect Dis. 2012;12:219. doi:10.1186/1471-2334-12-219.
58. Kapologwe N, Mori AT, Chilunda F, Meshack M, Kalolo A, Wiedenmayer K. Reforming supportive supervision of medicines management with an audit tool in primary health care facilities: a case study of Bahi District. Tanzania. Int J Pharm. 2014;4(4):108–14.